Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in Enterobacterales

被引：8

作者：

Sadek, Mustafa ^{[1
,2
]}

Duran, Juan Bosch ^{[1
]}

Poirel, Laurent ^{[1
,3
]}

Nordmann, Patrice ^{[1
,3
,4
]}

机构：

[1] Univ Fribourg, Fac Sci & Med, Med & Mol Microbiol, Fribourg, Switzerland

[2] South Valley Univ, Fac Vet Med, Dept Food Hyg & Control, Qena, Egypt

[3] Univ Fribourg, Swiss Natl Reference Ctr Emerging Antibiot Resista, Fribourg, Switzerland

[4] Univ Lausanne, Univ Hosp Ctr, Inst Microbiol, Lausanne, Switzerland

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2023年 / 67卷 / 05期

基金：

瑞士国家科学基金会;

关键词：

minor carbapenemases; SME; Enterobacterales; imipenem-relebactam; FRI; NMC-A; carbapenemase;

D O I：

10.1128/aac.00078-23

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam, and cefiderocol was evaluated against both clinical and isogenic enterobacterial isolates producing carbapenemases of the SME, NmcA, FRI, and IMI types. Ceftazidime-avibactam and meropenem-vaborbactam showed the highest activity against all tested isolates; imipenem-relebactam showed only moderate activity. All isolates remained susceptible to cefiderocol. Furthermore, avibactam and vaborbactam have greater inhibitory activity than relebactam against the tested carbapenemases. Overall, ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol were the most effective therapeutic options for treating infections caused by the tested minor carbapenemase producers.

引用

页数：5